Treatment Guidelines for Axial Spondyloarthritis

Sonam Kiwalkar, Atul Deodhar, Joachim Sieper

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Scopus citations

Abstract

As novel therapeutic agents become available for the treatment of axial spondyloarthritis (axSpA), management decisions in daily practice become complicated. Moreover, medication approval and cost vary widely by geography. Treatment recommendations for management of axSpA are therefore developed by many national societies. The two most widely publicized are treatment recommendations developed by the Assessment of SpondyloArthritis International Society/European League against Rheumatism (ASAS-EULAR), (Van Der Heijde et al., 2017)1 and by the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network (ACR/SAA/SPARTAN) (Ward et al., 2016). Both propose a step-up approach for nonpharmacologic and pharmacologic treatments. This chapter addresses the science of development of treatment recommendations, similarities and differences between these two sets of recommendations and explores their implications on patient management.

Original languageEnglish (US)
Title of host publicationAxial Spondyloarthritis
PublisherElsevier
Pages243-258
Number of pages16
ISBN (Electronic)9780323568005
DOIs
StatePublished - Jan 1 2019
Externally publishedYes

Keywords

  • Ankylosing spondylitis
  • Axial spondyloarthritis
  • Treatment guidelines
  • Treatment recommendations

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Treatment Guidelines for Axial Spondyloarthritis'. Together they form a unique fingerprint.

Cite this